Table 4.
Multivariate analysis of long‐term HCT outcomes for AML.
| Relapse | NRM | LFS | OS | CGRFS | Chronic GVHD | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | p Value | HR (95% CI) | p Value | HR (95% CI) | p Value | HR (95% CI) | p Value | HR (95% CI) | p Value | HR (95% CI) | p Value | |
| Donor MSC (ref) | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| UD | 0.84 (0.72–0.98) | 0.026 | 1.28 (1.07–1.53) | 0.008 | 1.01 (0.9–1.14) | 0.88 | 1 (0.88–1.13) | 0.97 | 1.06 (0.95–1.18) | 0.31 | 1.13 (0.88–1.46) | 0.33 |
| Other relative | 0.59 (0.37–0.95) | 0.031 | 1.5 (0.99–2.26) | 0.054 | 0.93 (0.68–1.26) | 0.63 | 0.99 (0.71–1.38) | 0.98 | 0.93 (0.7–1.23) | 0.61 | 0.92 (0.48–1.76) | 0.8 |
| CR2/3 | 1.16 (0.97–1.4) | 0.11 | 1.12 (0.91–1.38) | 0.3 | 1.14 (0.99–1.31) | 0.063 | 1.15 (0.98–1.34) | 0.082 | 1.17 (1.03–1.33) | 0.018 | 1.25 (0.94–1.66) | 0.13 |
| Active disease | 1.7 (1.43–2.01) | <0.0001 | 1.48 (1.21–1.81) | <0.0001 | 1.59 (1.4–1.81) | <0.0001 | 1.65 (1.43–1.9) | <0.0001 | 1.49 (1.32–1.69) | <0.0001 | 1.25 (0.92–1.71) | 0.15 |
| Age (per 10 y) | 1.12 (1.06–1.19) | 0.0002 | 1.43 (1.32–1.54) | <0.0001 | 1.24 (1.18–1.3) | <0.0001 | 1.3 (1.23–1.37) | <0.0001 | 1.19 (1.14–1.25) | <0.0001 | 1.09 (0.99–1.19) | 0.092 |
| Year of HSCT | 1.04 (1.01–1.08) | 0.021 | 1 (0.96–1.04) | 0.86 | 1.02 (1–1.05) | 0.089 | 1.01 (0.98–1.04) | 0.47 | 1.03 (1.01–1.06) | 0.008 | 1.08 (1.01–1.14) | 0.014 |
| Cytogenetics (Ref = Favorable risk)a | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Intermediate | 1.57 (1.11–2.22) | 0.011 | 1.02 (0.72–1.45) | 0.91 | 1.29 (1.01–1.66) | 0.042 | 1.27 (0.96–1.68) | 0.088 | 1.32 (1.06–1.66) | 0.015 | 1.42 (0.86–2.36) | 0.18 |
| Adverse | 3 (2.06–4.36) | <0.0001 | 1.16 (0.76–1.79) | 0.49 | 2.06 (1.56–2.72) | <0.0001 | 2.27 (1.67–3.09) | <0.0001 | 2.09 (1.62–2.69) | <0.0001 | 1.96 (1.1–3.5) | 0.022 |
| Missing | 1.55 (1.1–2.18) | 0.011 | 1.05 (0.75–1.48) | 0.78 | 1.3 (1.02–1.66) | 0.031 | 1.32 (1.01–1.74) | 0.043 | 1.34 (1.07–1.67) | 0.009 | 1.42 (0.87–2.32) | 0.16 |
| RIC vs. MAC | 1.08 (0.92–1.25) | 0.35 | 1.21 (1.01–1.44) | 0.039 | 1.15 (1.02–1.29) | 0.021 | 1.21 (1.06–1.37) | 0.004 | 1.07 (0.97–1.2) | 0.19 | 0.75 (0.58–0.97) | 0.028 |
| TBI | 0.81 (0.69–0.95) | 0.009 | 0.99 (0.83–1.17) | 0.87 | 0.89 (0.79–1) | 0.054 | 0.91 (0.8–1.03) | 0.14 | 0.93 (0.84–1.04) | 0.22 | 1.12 (0.89–1.42) | 0.33 |
| PB vs. BM | 0.99 (0.81‐1.21) | 0.93 | 1.45 (1.11–1.89) | 0.006 | 1.16 (0.99–1.37) | 0.065 | 1.2 (1–1.43) | 0.048 | 1.13 (0.98–1.31) | 0.095 | 1.15 (0.84–1.57) | 0.39 |
| Female to male donor | 0.91 (0.76‐1.1) | 0.33 | 1.72 (1.44–2.06) | <0.0001 | 1.22 (1.08–1.39) | 0.002 | 1.32 (1.15–1.51) | <0.0001 | 1.16 (1.03–1.3) | 0.018 | 0.87 (0.64–1.17) | 0.35 |
| KPS > = 90 | 0.96 (0.82‐1.12) | 0.58 | 0.87 (0.73–1.03) | 0.11 | 0.92 (0.82–1.03) | 0.16 | 0.9 (0.79–1.02) | 0.097 | 0.95 (0.85–1.05) | 0.32 | 1.11 (0.84–1.46) | 0.46 |
| in vivo TCD | 1.14 (0.97‐1.34) | 0.11 | 0.48 (0.4–0.57) | <0.0001 | 0.78 (0.69–0.88) | <0.0001 | 0.67 (0.59–0.76) | <0.0001 | 0.74 (0.66–0.82) | <0.0001 | 0.6 (0.46–0.77) | <0.0001 |
Abbreviations: ALL, acute lymphoblastic leukemia; BM, bone marrow; CGRFS, cGVHD‐free, relapse‐free survival; CI, confidence interval; GVHD, graft‐versus‐host disease; HCT, hematopoietic cell transplantation; HR, hazard ratio; LFS, leukemia‐free survival; MAC, myeloablative conditioning; NRM, nonrelapse mortality; OS, overall survival; PB, peripheral blood; RI, relapse incidence; RIC, reduced intensity conditioning; TCD, T cell depletion.
a
As a missing category was included in the model, HR are not reliable for cytogenetics.